Axinn Advised Thermo Fisher on $1.85B Acquisition of PeproTech, Inc.
January 5, 2022
Axinn represented Thermo Fisher Scientific Inc., the world leader in serving science, in its approximately $1.85 billion acquisition of PeproTech, Inc., a leading developer and manufacturer of recombinant proteins. The deal closed on December 30, 2021. The Axinn antitrust team included partners John Harkrider and Mark Alexander, who were assisted by Craig Minerva, Tasneem Chowdhury, Megan Walden, and Kyle Sherwood.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
CCWC 22nd Annual Career Strategies Conference
Sponsorship
Fordham Competition Law Institute's 53rd Annual Conference on International Antitrust Law and Policy, and Antitrust Economics Workshop
Sponsorship
Antitrust
Women, Influence, & Power in Law Conference 2026
Sponsorship
Antitrust
IP Litigation North America Summit 2026
Sponsorship
Intellectual Property
HNBA/VIA Annual Convention 2026
Sponsorship
Antitrust
The DOJ’s Antitrust Whistleblower Rewards Program
Webinar
Antitrust
30th Annual IBA Competition Conference
Speaking Engagement
Antitrust
ABA 2026 Antitrust Global Seminar Series
Speaking Engagement
Antitrust
Another HSR Penalty Record: KKR’s $250 Million Settlement
Axinn Viewpoints
Antitrust
Do I Really Need To File? HSR Avoidance and the Edwards/Genesis Settlement
Podcast
Antitrust